Zanamivir

From Proteopedia

proteopedia linkproteopedia link

spinqualitylabelsall models Zanamivir, better known as Relenza, (3b7e) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image

Better Known as: Relenza

• Marketed By: GlaxoSmithKline
• Major Indication: Influenza Infection
• Drug Class: Neuraminidase Inhibitor
• Date of FDA Approval (Patent Expiration): 1999 (2016)
• 2009 Sales:$1.1 Billion
• Importance: It was the first neuraminidase inhibitor to be approved by the FDA, followed a few months later by Oseltamivir. Newer strains of flu virus, primarily H1N1, have developed varying levels of resistance to Oseltamivir, but a lesser extent to Zanamivir. Sales have increased dramatically since 2006 with scares of bird flu and swine flu pandemics.
• See Pharmaceutical Drugs for more information about other drugs and diseases.

Mechanism of Action

Pharmacokinetics

Neuraminidase Inhibitor Pharmacokinetics Parameter Zanamivir Oseltamivir Tmax (hr) 1.25 1.5 Cmax (ng/ml) 31.6 57 Bioavailability (%) 2 75 Protein Binding (%) 10 42 T1/2 (hr) 3 3.2 AUC (ng/ml/hr) 185 204 Clearance (L/h) 54.1 18.8 Dosage (mg) 10 300 Metabolism None Hepatic For References to Pharmacokinetic data, see: References

References